Background and aim: Hepatocellular carcinoma (HCC) has an increasing incidence worldwide. In this study we aimed to assess the prevalence of HCC among HCV patients in our center in Mid Delta, Egypt. Patients and methods: During the period between April 2013 and January 2015, we screened sequentially chronic HCV patients attending inpatient wards or outpatient Clinic of Tropical Medicine Department in Tanta University Hospital for HCC. Individuals with focal lesion in Ultrasound (US) and/or serum a-fetoprotein (AFP) level >200 ng/ml were examined by triphasic computed tomography scanning (CT), and/or magnetic resonance imaging (MRI). Results: Among 514 HCV patients interviewed and accepted sharing in this study, 90 (17.5%), 144 (28%), and 280 (54.5%) were Child A, B, and C, respectively. We found that 108/514 patients (21%) had focal lesion detected by US. Also, 89/514 (17.3%) had elevated AFP >200, 13 of them (14.6%) had no focal lesion on US, but further work up showed HCC in 2 of them. Overall HCC diagnosis was confirmed in 103 cases, 94 of them (91.3%) were Child B or C. Occurrence of HCC was significantly higher in smokers, diabetics, patients with decompensated liver and those with positive family history of HCC. Only 20/103 (19.4%) were candidates to curative treatments, 8 of them were Child A asymptomatic and discovered accidentally during screening.
Introduction
Hepatocellular carcinoma (HCC) has an increasing incidence worldwide. It is the second cause of cancer-related death worldwide [1, 2] . Patients with chronic infection with hepatitis B or C viruses are at higher risk for developing HCC, and should be enrolled into surveillance programs using ultrasound and serum a-fetoprotein (AFP) [3] .
In Egypt, HCC is the second most common cancer in men and the 6th most common cancer in women [4] . Hospital-based studies from Egypt have reported an overall increase in the relative frequency of all liver-related cancers in Egypt, from approximately 4% in 1993 to 7.3% in 2003 [5] . Former studies in Egypt have shown the increasing importance of HCV infection in the etiology of liver cancer, estimated to account for 40-50% of cases, and the declining influence of HBV and HBV/HCV infection (25% and 15%, respectively) [5, 6] .
Individuals with focal lesions in ultrasound examination require further examination with triphasic computed tomography (CT), magnetic resonance imaging (MRI), and/or liver biopsy to confirm a diagnosis of HCC [7] .
Treatment is effective in the early stages of the disease. Unfortunately, HCC is diagnosed in most patients at a time when curative surgical resection or organ transplantation cannot be performed because of advanced disease or substantial impairment of liver function [8] .
Barcelona Clinic Liver Cancer (BCLC) staging system is a widely used classification method which takes into account variables related to tumor stage, liver function, physical status and cancer-related symptoms (with performance status scale 0-4 where 0 equal normal physical performance and 4 is bed ridden) to generate a treatment algorithm [9] . In brief, at stage 0 patients are optimal candidates for resection. At stage A patients are candidates for radical therapies (resection, liver transplantation or percutaneous treatments). At stage B patients may benefit from chemoembolization. At stage C patients may receive new agents as part of RCT and lastly at stage D patients had end-stage disease and can receive only symptomatic treatment [10] . This classification was suggested to be best suited for treatment guidance, especially for patients who could benefit from curative therapies [11, 12] .
Aim of the work
In this study we aim to assess the prevalence of HCC among chronic HCV patients in our center in Mid Delta, Egypt.
Patients and methods

Study design
This is a cross-sectional study.
Study setting
The study was conducted at the Department of Tropical Medicine and Infectious Diseases at Tanta University Hospital, Tanta, Egypt between April 2013 and January 2015.
Participants
All adult patients with chronic HCV were prospectively recruited from the outpatient clinics and inpatient wards of Tropical Medicine and Infectious Diseases Department at Tanta University Hospital, Tanta, Egypt. All cases were screened for HCC using ultrasonography and AFP. Individuals with solid focal lesion in ultrasound examination, and/or serum AFP level >200 ng/ml were examined by tri-phasic CT, and/or MRI to confirm or roll out the diagnosis of HCC. Abdominal ultrasound examination, Complete blood counts with manual differential count, liver function tests, fasting blood sugar, and AFP levels were performed for all patients.
Inclusion criteria
Patients with positive anti HCVAb who had clinical and or laboratory findings suggestive of chronic liver disease (portal hypertension, splenomegaly, hyperbilirubinemia, coagulation defects. . .etc).
Exclusion criteria
Patients with diagnosed HCC, hepatic metastasis, and prior HCC treated lesions.
Ethical consideration
-The study protocol has been approved by Tanta University ethics committee. -All participating patients provided informed consent before taking part in the study.
Statistical analysis
Data were analyzed using SPSS version 16.0 (IBM Corp, Armonk, NY, USA). Quantitative values are expressed as mean ± SD. Qualitative data were expressed as numbers and percentages, and the Chi-square test and T-test was applied to compare the relationship between variables. The sensitivity, specificity, positive and negative predictive values of AFP were assessed at different cut off values using 2 Â 2 contingency tables. AFP levels were correlated to tumor size and multiplic-ity using Spearman's rho correlation test. A p-value of < 0.05 was considered statistically significant for all used tests.
Results
Our patients had age range of 29-78 with an average age of 55.13 ± 9.82 years. Among 514 patients shared in this study, 108 patients (21%) had focal lesion detected by ultrasonographic examination, 32 patients of them (29.6%) had AFP levels <200 ng/ml. Out of those 108 patients, 101 were confirmed to have HCC while the remaining 7 cases were diagnosed by either CT or MRI as follow (focal fat spared nodule in 3 cases, cirrhotic nodule in 4 cases); these 7 cases were categorized as not having HCC in statistical analysis.
On the other hand, 89/514 (17.3%) had elevated AFP >200 ng/ml; 13 of them (14.6%) had no focal lesion in ultrasound, but further work up showed HCC in 2 of them. Overall, HCC diagnosis was confirmed in 103 cases, their demographic and clinical data are compared to HCV patients and revealed that age, sex and residence were not significantly different between the two groups. HCC was more prevalent in association with positive family history of HCC (it was considered positive if any of first or second degree relatives were diagnosed as a HCC patient, regardless of their medical management or survival). Patients who suffer diabetes comorbidity, hematemesis, encephalopathy, right hypochondrial pain, ascites, jaundice, combined positivity of HCV Ab and HBsAg, higher Child Pugh score, and high serum AFP were significantly more associated with occurrence of HCC ( Table 1) .
The frequency of AFP elevation above 100, 200 ngm/ml was presented as contingency table (Table 2 a,b). Accordingly, AFP has sensitivity, specificity positive predictive value and negative predictive values of 76.7%, 88.6%, 62.7%, 93.8% and 75.7%, 97.3%, 87.6%, 94.1% at cut off value 100 and 200 ng/ml, respectively (Table 3) .
AFP was positively correlated to ChildPugh score (r = 0.217, p = 0.014), but not correlated to tumor size (r = 0.016, p = 0.437) or multiplicity (r = 0.147, p = 0.069).
The tumor was presented as single focus, 2 foci, and multiple foci in 78, 14 and 11 patients, respectively. Twenty-two patients had bi-lobar affection. Fifty patients had their tumor diameter >5 cm ( 
Discussion
HCC diagnosis was confirmed in 103/514 (20.03%) of our patients. Similar results were obtained by Atti et al. [14] who reported that prevalence of HCC among CLD Egyptian patients was 21%. Egypt and particularly Nile delta has the highest prevalence of HCV worldwide rendering more patients prone to post hepatitis C cirrhosis and HCC [11] . Moreover, many non-viral environmental factors as aflatoxin and pesticides are common in this region and can participate in the pathogenesis of HCC through mutations and serious damage in DNA which can act as cofactors for chronic viral hepatitis to cause cancer [13, 15] . These factors besides the early detection of some asymptomatic cases can all collaborate to give this annoying high figure reported in our patients.
In HCC, male predominance is more obvious in population at high risk with male to female ratio 3.7:1 [16] . This observation was confirmed by our results. The M/F ratios were 4/1 and 3/1 in HCC and HCV patients, respectively. Besides the higher ratio of males in HCV infection, the male predominance in HCC may be explained by greater exposure of males to other environmental carcinogens [17] , a role for sex hormones, and higher DNA synthetic activities in male cirrhotic patients compared to females [17] . The mean age of our HCC patients was 57.5 years. Similar results were reported by Mohamed et al. [16] and Tangkijvanich et al. [17] who reported a mean age of 56, and 52.6 years, respectively. As in areas with high risk for HCC, the mean age for HCC is usually younger [16] ; it was not surprising to find no significant difference in age between HCV and HCC patients.
In this study, more than 84% of our patients were from rural areas. These results are explained as most of Mid Delta are rural areas. Also, El-Zayadi et al. [5] stated that 75.2% of his HCC population resided in rural areas. This higher prevalence may be explained by the nature of rural area residences where the population is more exposed to environmental pollutants as pesticides and herbicides.
Diabetes is associated with a 2-3-fold increase in the risk of HCC; regardless of the presence of other major HCC risk factors [18] . This was in accordance with the significant higher frequency of DM in our HCC patients.
Smoking increases the risk of HCC in patients with viral hepatitis. Cigarettes are a major source of 4-aminobiphenyl; a hepatic carcinogen which has been implicated as a causal risk factor for HCC. Tobacco smoking is associated with reduction of tumor suppressor gene p53 and accumulation of excess iron in hepatocytes in heavy smokers, which induces fibrosis and favors development of HCC [19, 20] . In our study, there was no significant difference between percent of smokers in both groups. This was in agreement with Mori et al. [21] who find the increased risk of HCC in smokers to be non-significant after adjusting for age and gender, and Franceschi et al. [22] who concluded that tobacco smoking was unrelated to overall HCC risk.
Coffee consumption of more than 3 cups per day may be associated with reduced risk to HCC [23] . In our study, this degree of coffee consumption was less frequent in HCC patients. Yet the difference was not statistically significant.
Co-infection with HBV was significantly higher in HCC compared to HCV groups (11.7% versus 4.6%). These results were in agreement with Zampino et al. [24] who stated that HBV and HCV co-infection is associated with more rapid progression to HCC.
The frequency of Rt. hypochondrial pain, Jaundice, Ascites, Hepatic encephalopathy, and hematemesis was significantly higher in HCC patients compared to chronic HCV patients. This explained that HCC development is a leading cause for deterioration of CLD patients [25] .
Abdominal ultrasound is the most common imaging modality used in the surveillance of HCC [26] . However, the accuracy of ultrasound is dependent on the operators and their ability to differentiate HCC from non-neoplastic lesions such as regenerative nodules [27] . In our work, ultrasound was able to detect focal lesion in most cases of HCC which confirms its leading screening role. Adding AFP examination augments the screening role of ultrasound. However, the rise in the serum AFP level did not correlate with the tumor size or number. The lack of correlation could be explained by the fact that tumor differentiation and its ability to secrete AFP are more important than the tumor size in determining the level of AFP produced by HCC [28] . Sawabu et al. [29] declared that small tumors tend to express lower levels of AFP, although there is no clear direct relation between the tumor size and AFP levels, because individual tumors have different capacities for AFP synthesis, also it is difficult to measure viable tumor cell mass accurately and thereby to investigate the true correlation between viable tumor mass and AFP.
In the current study, there was a significant positive correlation between AFP and the Child Pugh score in HCC group. This may be attributed to the presence of underlying chronic liver disease with subsequent cirrhosis and the progressive deterioration of the liver condition. Elevated AFP in these patients is not indicative but may be only suggestive of HCC and needs further work-up to exclude HCC [26] . At cut off value 200 ng/ml, we found AFP to be 75.7% sensitive and 97.3% specific in diagnosis of HCC, which may encourage using it in screening being a cheap and easy test. When we test a cut off value of 100 ng/ml, AFP was 76.7% sensitive, but specificity dropped to 88.6%. Cost effective studies are needed before adopting 100 ng/ml as a cut off value for HCC in cirrhotic patients.
In spite of the obvious advantages of early intervention in HCC and the very limited treatment options for patients in advanced stages, surveillance measures are not routinely implemented [30] . A recent Canadian study found that most patients with HCC referred to a tertiary liver treatment center were in palliative stages [31] . Regarding the treatment options for our 103 HCC patients, 54/103 (52.4%) had advanced HCC (stage C or D) and just received supportive therapy, while, 49/103 (47.9%) were treated with different modalities as follows: 5/49 (10.2%) surgical excision, 15/49 (30.7%) radiofrequency (RF) ablation, 8/49 (16.3%) alcoholic injection, and 21/49 (42.8%) trans arterial chemo embolization (TACE). So, only 20/103 (19.4%) were diagnosed in stages allowing for curative treatment. These findings stress on the importance of strict implementation of routine screening and surveillance for patients with HCV and cirrhosis to detect liver cancer in early stages where there is a chance for curative therapy.
Conclusion
The prevalence of HCC in our patients was 22%. HCC was more prevalent in HCV patients with positive family history of HCC, DM, HBV comorbidity, right hypochondrial pain, hematemesis, encephalopathy, ascites, jaundice, and higher Child Pugh score indicating higher prevalence in decompensated cirrhosis. Only 19.4% of HCC patients were diagnosed in the early stage rendering them candidate for curative treatment. A national surveillance program for HCC in cirrhotic HCV Egyptian patients by combining ultrasound examination and AFP is highly recommended.
